The Centers for Medicare & Medicaid Services May 7 issued a final rule that implements the standards governing health insurance issuers and the Health Insurance Marketplaces (or “exchanges”) for 2021.

In the rule, CMS finalized the benefit and payment parameters for qualified health plan issuers selling on the exchanges, as well as additional policies intended to lower premiums, promote program integrity, stabilize the individual and small group markets, enhance the consumer experience and reduce regulatory burden.

Also in the rule, CMS finalized value-based insurance design options that QHP issuers can choose to implement; updated how cost sharing calculations will account for drug manufacturer coupons; finalized small updates to medical loss ratio and special enrollment period rules; and increased the annual maximum out-of-pocket spending limits.

CMS did not finalize its proposal to require enrollees with no premium after a premium tax credit is applied to actively re-enroll or face reduced subsidies, consistent with AHA’s comments on the proposed rule.

Download the Special Bulletin for a summary of the key issues.

Related News Articles

Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…
Headline
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned…
Headline
All 50 states have applied for the Rural Health Transformation Program, the Centers for Medicare & Medicaid Services announced Nov. 5. The program will…
Headline
Bill Gassen, Sanford Health president and CEO and AHA chair-elect designate, and Deb Koski, Sanford Health chief philanthropy officer, discuss how a strong…
Headline
The AHA and a coalition of organizations yesterday urged House and Senate leaders to pass the Reforming and Enhancing Sustainable Updates to Laboratory Testing…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…